Prognostic factors in superficial adult soft tissue sarcomas : Analysis of a series of 105 patientsCANY, L; STOECKLE, E; COINDRE, J.-M et al.Journal of surgical oncology. 1999, Vol 71, Num 1, pp 4-9, issn 0022-4790Article

Standards, Options et Recommandations 2001 pour la radiothérapie des patientes atteintes d'un cancer du sein infiltrant non métastatique, mise à jour = 2001 updated Standard Options and Recommendations for radiotherapy in non metastatic breast cancer patientsFOURQUET, A; CUTULI, B; BALU-MAESTRO, C et al.Cancer radiothérapie. 2002, Vol 6, Num 4, pp 238-258, issn 1278-3218Article

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens : Results of a randomized phase III trialRAVAUD, A; CHEVREAU, C; TABAH, I et al.Journal of clinical oncology. 1998, Vol 16, Num 9, pp 2930-2936, issn 0732-183XArticle

A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le CancerBECOUARN, Y; SENESSE, P; THEZENAS, S et al.Annals of oncology. 2007, Vol 18, Num 12, pp 2000-2005, issn 0923-7534, 6 p.Article

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trialRAVAUD, A; TRUFFLANDIER, N; FERRIERE, J. M et al.British journal of cancer. 2003, Vol 89, Num 12, pp 2213-2218, issn 0007-0920, 6 p.Article

Prise en charge de l'anémie en oncologie: modalités pratiques, efficacité des agents stimulant l'érythropoïèse (ASE) [darbépoétine alpha] et place de la transfusion = Managenent of anaemia in the oncology department: practical methods, effectiveness of erythropoiesis-stimulating agents (ESA) [darbepoetin-alplia] and the role of the transfusionLEVACHE, B; SOUSSELIER, B; CANY, L et al.Oncologie (Paris). 2012, Vol 14, Num 2, pp 123-130, issn 1292-3818, 8 p.Article

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanomaRAVAUD, A; LEGRAND, E; BUI, B. N et al.British journal of cancer. 1995, Vol 71, Num 2, pp 331-336, issn 0007-0920Article

Chimiothérapie d'induction et traitement combiné conservateur des sarcomes des tissus mous de l'adulte = Neoadjuvant chemotherapy and conservative local treatment for soft tissue sarcomas in adultsCANY, L; BUI, N. B; STÖCKLE, E et al.Bulletin du cancer. 1992, Vol 79, Num 11, pp 1077-1085, issn 0007-4551Article

Lymphomes anaplasiques T ou nuls à grandes cellules CD30⁺ (Ki-1) de l'adulte = Adult's anaplastic CD30⁺ large cell lymphomasCANY, L; SOUBEYRAN, P; BOULANGER, V et al.Bulletin du cancer. 1999, Vol 86, Num 9, pp 739-744, issn 0007-4551Article

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinomaRAVAUD, A; NEGRIER, S; CANY, L et al.British journal of cancer. 1994, Vol 69, Num 6, pp 1111-1114, issn 0007-0920Conference Paper

Expression of MDR1/P glycoprotein in human sarcomasVERGIER, B; CANY, L; BONNET, F et al.British journal of cancer. 1993, Vol 68, Num 6, pp 1221-1226, issn 0007-0920Article

Effets secondaires de l'interleukine 2 = Side effects of interleukin 2RAVAUD, A; NEGRIER, S; LAKDJA, F et al.Bulletin du cancer. 1991, Vol 78, Num 11, pp 989-1005, issn 0007-4551Article